Kezar Life Sciences said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and focus on developing the drug for a rare chronic ...
Due to its rarity and overlapping symptoms with other conditions, SPS is frequently misdiagnosed ... ADI-001 was granted Fast Track Designation by the FDA for the treatment of relapsed/refractory ...
The Lupus Foundation of America (LFA) is excited to announce Karen Costenbader is the recipient of the LFA’s 2024 Predict and Prevent Lupus Research grant.